Author Archives: admin


AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntingtons Disease and Other…

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced a research collaboration with the University of California, Irvine (UCI) using AgeXs PureStem technology to derive neural stem cells, with the goal of developing cellular therapies to treat neurological disorders and diseases for which there are no cures. The collaborations initial R&D work, expected to take approximately one year, will be conducted in the UCI laboratory of Leslie Thompson, PhD, Chancellors Professor of Psychiatry & Human Behavior and Neurobiology & Behavior, a leading researcher in the field of Huntingtons disease and other neurological disorders, under a Sponsored Research Agreement handled by the Industry Sponsored Research team at UCI Beall Applied Innovation. The initial focus will be on Huntingtons disease, while other potential targets may include Parkinsons, Alzheimers, and stroke.

The primary goal of the research will be to develop a robust method of deriving neural stem cells from pluripotent stem cells in sufficient quantity and with sufficient purity and identity for use in cell-based therapy. Professor Thompsons laboratory has already accumulated safety and efficacy animal data that may support an IND submission to the FDA as early as 2021 for the commencement of clinical trials to treat Huntingtons disease.

"We look forward to utilizing AgeXs cell derivation and manufacturing PureStem technology, with its many potential advantages, including industrial scalable manufacturing, lower cost of goods, and clonal cells with high purity and identity. Our goal is to have an improved neural stem cell production method ready within a year to move into clinical development," said Professor Thompson.

"We are absolutely delighted to start this exciting collaboration with Professor Thompson, who has worked tirelessly over her career to develop a neural stem cell product candidate for Huntingtons disease and who has already generated preclinical animal data that may support the initiation of clinical studies," said Dr. Nafees Malik, Chief Operating Officer of AgeX. "Moreover, we are very excited to be entering the field of neurology, which has huge clinical and commercial potential. Neural stem cells may be very useful in other neurological disorders that are common in aging demographics, such as Parkinsons, Alzheimers and stroke."

"This is an example of the kind of collaboration we will be seeking under our newly-unveiled collaboration and licensing strategy, which is to run parallel to our in-house product development," said Dr. Greg Bailey, Chair of AgeX. "We will be collaborating with a world leader in their field on a research project which is close to the clinic."

The collaboration includes an opportunity for AgeX to organize a company to be jointly owned with Professor Thompson and other researchers to pursue clinical development and commercialization of cell therapies derived using licensed inventions arising from the research program, as well as certain patent pending technology for neural stem cell derivation, and certain technical data, including animal data, to support IND submissions.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

Story continues

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates" should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries particularly those mentioned in the cautionary statements found in more detail in the "Risk Factors" section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Further, in the case of AgeXs new neural stem cell program there can be no assurance that: (i) any new cell derivation methods will be invented in the sponsored research program, (ii) any derivation methods that may be developed will be sufficient to derive neural stem cells in quantities and of purity suitable for clinical use and commercialization, (iii) that any new inventions or existing technology will be licensed on commercially favorable terms, (iv) that any neural stem cells derived for therapeutic use will be shown to be safe and effective in clinical trials, and (v) that any neural stem cells derived for therapeutic use will be successfully commercialized even if clinical trials are successful. Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005261/en/

Contacts

Media Contact for AgeX: Bill Douglass Gotham Communications, LLC bill@gothamcomm.com (646) 504-0890

View post:
AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntingtons Disease and Other...

PRP: Cost, Side Effects, and Recovery

Platelet-rich plasma, or PRP, is a substance thats thought to promote healing when injected. Plasma is a component of your blood that contains special factors, or proteins, that help your blood to clot. It also contains proteins that support cell growth. Researchers have produced PRP by isolating plasma from blood and concentrating it.

The idea is that injecting PRP into damaged tissues will stimulate your body to grow new, healthy cells and promote healing. Because the tissue growth factors are more concentrated in the prepared growth injections, researchers think the bodys tissues may heal faster.

The treatment hasnt been definitively proven. It also hasnt been approved as a treatment by the U.S. Food and Drug Administration. However, famous athletes like Tiger Woods and tennis star Rafael Nadal have been known to use these injections to help heal injuries.

Researchers are trying out PRP injections across a number of applications. Examples of these include:

Hair loss: Doctors have injected PRP into the scalp to promote hair growth and prevent hair loss. According to research from 2014, PRP injections are effective in treating androgenic alopecia, which is also known as male pattern baldness.

Tendon injuries: Tendons are tough, thick bands of tissue that connect muscle to bone. They are usually slow to heal after injury. Doctors have used PRP injections to treat chronic tendon problems, such as tennis elbow, Achilles tendonitis at the ankle, and jumpers knee, or pain in the patellar tendon in the knee.

Acute injuries: Doctors have used PRP injections to treat acute sports injuries, such as pulled hamstring muscles or knee sprains.

Postsurgical repair: Sometimes doctors use PRP injections after surgery to repair a torn tendon (such as a rotator cuff tendon in the shoulder) or ligaments (such as the anterior cruciate ligament, or ACL).

Osteoarthritis: Doctors have injected PRP into the knees of people with osteoarthritis. A 2015 study found that PRP injections were more effective than hyaluronic acid injections (a traditional therapy) for treating osteoarthritis. However, the trial was a small group of 160 people, so larger trials are needed for this to be conclusive.

Its important to note that none of these uses have been definitively proven to provide results.

Read more: 5 exercises for rotator cuff pain

Generally speaking, there are few steps to preparing for PRP injections.

However, PRP can be injected in different ways. For example, sometimes a topical numbing lidocaine solution is applied to your scalp before injection. You may have to arrive early to a treatment session for this to be applied.

Other times, a local anesthetic is mixed with the PRP to reduce any discomfort. Sometimes, your doctor will inject or apply PRP during a surgery. In this instance, preparation for PRP injections would involve following your surgeons recommendations presurgery.

Heres what to expect from a typical PRP injection process:

According to Emory Healthcare, this process usually takes around one hour.

According to the American Academy of Orthopaedic Surgeons, very few insurance plans will provide any reimbursement for PRP injections. The costs must largely be paid out-of-pocket. The costs can also vary from location to location and on how the injections are used. Some of the reported costs nationwide include the following:

Insurance companies consider PRP an experimental treatment. More scientific research will have to conclude its effectiveness before it is more widely covered.

Because PRP involves injecting a substance into the skin, there are potential side effects. PRP is autologous, which means it contains substances that come directly from your own body. This reduces the risks for an allergic reaction that can occur from injecting other medications, such as cortisone or hyaluronic acid. However, there are risks from the injection itself, including:

You should discuss these potential risks with your doctor, as well as the steps your doctor will take to minimize these risks.

When PRP is injected following injury, your doctor may recommend that you rest the affected area. However, these recommendations are more related to the injury and less to the PRP injections. Most people can continue their daily activities following PRP injections.

Because PRP injections are intended to promote healing or growth, you may not notice an immediate difference after receiving the injections. However, in several weeks or months, you may observe that the area is healing faster or growing more hair than you would have expected if you hadnt received PRP injections.

See the rest here:
PRP: Cost, Side Effects, and Recovery

Platelet-Rich Plasma: Does It Work? – www.PainScience.com

An interesting treatment idea for arthritis, tendinopathy, muscle strain and more

PaulIngraham, updated Jan 25, 2020

Give your blood toyourself!

Blood therapy, anyone? Platelet-rich plasma (PRP) injections bathe troubled cells in a concentrated mixture made from your own blood. Hopefully this stimulates healing where it is otherwise failing especially stubborn, slow-motion injuries like tendinitis1 but no one really knows for sure yet.

Despite all the not-knowing, its easy to pay someone to do this for you these days: extract some of your blood, spin it in a centrifuge to get the platelets, and then pump them back into you. Its not cheap, but PRP injections have become super popular, particularly with elite athletes (ever the guinea pigs for unproven, expensive new treatments for musculoskeletal injuries). It sounds perfect for injuries like patellofemoral pain, an extremely common pseudo-arthritis of the knee in runners,2 or IT band syndrome, another kind of common runners knee a huge potential market, in other words. In the fall of 2009, ScienceBasedMedicine.org scathingly criticized the marketing of PRP:3

Without any clear evidence of benefit beyond placebo, PRP is now being marketed aggressively as a cure-all for sports injuries. And at about $300 per injection (the NYT reports $2000/treatment), theres plenty of money to be made. a nation-wide marketing initiative has begun, using sports celebrities as guinea pigs.

~ A Case Study In Aggressive Quackery Marketing, Jones (ScienceBasedMedicine.org)

At that time, the problem was that the marketing was irresponsible in light of the lack of evidence. It was a short wait for more. Today, the marketing is irresponsible in light of the evidence we now have

Cynics can stop reading here. You know this doesnt end well. Theres a section summarizing all the major highlights from the literature further along here, but the bottom line is clear: if it works at all, its tricky and unreliable, probably heavily dependent on factors we dont understand and cannot control.

Stem cells are generic cells that do not yet have a job. In theory, they can become what we need them to be, which is a potentially powerful tool in medicine. Stem cell therapy is a broad concept in regenerative medicine, and it is a hot hot hot topic right now.

Stem cell therapy is identical in spirit to the other two main regenerative therapies in musculoskeletal and pain medicine: platelet-rich plasma and autologous chondrocyte implantation. But neither PRP or ACI is technically a stem cell therapy they use mature, specialized cells, so they are just cell therapies.

But regeneration is the goal of all of these methods, and the topic of stem cell therapy overlaps so much with PRP and ACI that they are practically the same thing regards to safety, efficacy, and the concerns of skeptical consumers and regulators. They are biologically intriguing treatments that might amount to something someday after all, we know regeneration is possible, thanks to salamanders! but its a depressing mess so far, instead of being inspiring and promising. These treatments are all being rushed to market in the same way, all sold as high-tech medicine to desperate consumers long before the science is done.

Meet the Clotters! Platelets are the major clotting tool in your blood, and they are curious critters, neither cells nor molecules, but a strange hybrid often called cell fragments: platelets are to blood cells what wood chips are to a log if the chips were extremely clever. Platelets have a bunch of interesting biological features, but they are best known for their work in clotting and thats mainly what gives them that healing mystique.

There are countless biochemical factors that regulate healing its complex, to say the least. Platelets are part of that equation, playing a critical role in tissue repair and regeneration; specifically they regulate fundamental mechanisms involved in the healing process including cellular migration, proliferation, and angiogenesis.4 Since they are involved in healing, more of them must be good, right?

That is the basic rationale for PRP.

The ruffled white one in the middle is a platelet an activated platelet, specifically. When calm, they are smaller &smoother.

In fact, PRP is often called regenerative medicine, because the idea of genuinely accelerated healing is so tantalizing, happy science fiction. But its more marketing than biology, surprise surprise.5 You could probably talk people into drinking a platelet smoothie if you told them it would regenerate them.

But it is not safe to assume a soup of platelets is regenerative. In fact, its not even safe to assume its safe

Health Canada isnt a fan, and notably they have safety concerns:6

Many emerging autologous cell therapy products may eventually prove to be safe and effective. However, most of these products are currently at the investigational stage of development with an on-going need to gather supporting scientific evidence.

Injecting medications into muscles might not be harmless. (No ones surprised by that, right? Good!) Anaesthetics and NSAIDs probably are a little myotoxic poisonous to muscles and theres conflicting evidence about PRP. It might be fine, but its important to bear in mind that faddish new injection treatments are never risk free.

Like a salad spinner

To make PRP, blood is spun in a centrifuge. Different blood components separate intolayers.

Who says more platelets stimulates healing? Is that in the Platelet User Guide? For extra healing, generously apply platelets to wound. Dosage is critical with many medicines. More is not only not always better, its usually worse. Do other cells like being bathed in ten times the normal number of platelets? Or is it a suffocating mess that throws everything off kilter?

Or is it just kind of ho hum?

In PRP marketing and hype, its common to see claims that its a natural treatment because its your own blood being returned to you, see? and what could be safer and healthier than you-stuff? But this is bio-illogical: theres lots of stuff inside of me that I do not want to be extracted, concentrated, and returned! Pick any hormone, for instance: many of those are just as involved in healing as platelets, but too much of most of them is just a disaster.

For instance, there is a disease of excessive iron, hemochromatosis a major component of red blood cells, essential to life, something you could easily think you want a lot of for vitality and healing. And indeed you do, if youre anemic. But chronically absorb too much, and its a serious disease.

What you want in biology is just-right amounts of everything, rarely lots of extra anything. Its really quite odd to assume that a platelet-rich sauce o blood is natural and safe and helpful just because the stuff came from you. Which is why this treatment needs to be tested, not assumed like every treatment.

In a 2018 podcast, I listened to a really credible expert guest boldly state that theres very strong evidence for platelet-rich plasma in osteoarthritis. Thinking I must have missed something, I checked the primary reference in the show notes, which is also still the most recent review of PRP for osteoarthritis. Did it back up the expert?

Not even close!7 As far as I can tell, there is just zero justification for what she said: its not very strong, its actually very weak. It exists, and its technically positive, but its just not compelling.

PRP fans and purveyors will tell you there is good evidence that PRP works, but they are cherry picking from a few studies that worked out in their favour one way or another. A few positive studies never not mean much; indeed, most positive study results are actually just bogus.8

Taken as a whole, the evidence is somewhere between inconclusive and discouraging. Although more research is needed (of course!) enough decent studies have now been done that the evidence reviews have started to come out.They all warn that most of the evidence is poor quality, and they are all basing their conclusions on just barely enough good data. They all emphasize that PRP methods are not standardized there are many versions of PRP, all based on speculation, not data.

The bad news got rolling in 2010. The New York Times reported9 (very) bad science news:

Now, though, the first rigorous study asking whether the platelet injections actually work finds they are no more effective than saltwater.

Nothing has improved significantly since. Highlights from the literature since then:

Three high-quality studies (75%) and two low-quality studies showed no significant benefit at the final follow-up measurement or predefined primary outcome score when compared with a control group. One high-quality study (25%) showed a beneficial effect of a PRP injection when compared with a corticosteroid injection (corticosteroid injections are harmful in tendinopathy). Based on the best evidence synthesis, there is strong evidence that PRP injections are not efficacious in chronic lateral epicondylar tendinopathy.

In early 2018, the journal Sports Medicine piled on with a review of six (crappy) studies of PRP for muscle injury (pulled muscles, strains).16 Even the optimistic expert I mentioned above expressed her doubts about PRP for muscle injury.

The promising biological rationale, the positive preclinical findings, and the successful early clinical experience of PRP injections are not confirmed by the recent high-level RCTs.

Meta-analysis is the research technique of pooling data from many studies to boost their statistical power. While often thought of as the pinnacle of scientific credibility, in fact meta-analysis is notoriously fallible. It particularly suffers from the garbage in, garbage out problem: its tough to extract meaningful results from pooled data when all the data sucks. The statistical complexity of such analysis also provides plenty of opportunity for bias-powered abuse and statistical jiggery pokery.

Meta-analysis just aint all its cracked up to be, and must be subjected to the same kind of critical analysis as any other kind of study/paper.

I used to rely on meta-analysis, but they are worse than laws & sausages, ceasing to inspire respect in proportion as we know how they are made.

~ Dr. Mark Crislip, "I Never Meta Analysis I Really Like"

Most of the good news coming from isolated or flawed studies. Isolated positive evidence about over-hyped treatments is a huge red flag, which usually means researchers made errors in their favour. Its the pattern of evidence that counts, and so far the pattern is distinctly bad.

Any hope? Maybe a little. There are different ways of doing PRP, and there different conditions in different stages may respond better or worse. Its biologically plausible that PRP could fail with chronic tendinitis but still succeed with an acute muscle strains, for instance, or even fail with one kind of muscle strain and succeed with another. Hammondetal, an experiment on rats rats were harmed and treated for our edification reported a difference between two kinds of muscle strain. It worked better on a more serious injury, where regeneration of muscle tissue was part of the healing process. PRP might assist with that regenerative process, but have no effect on a less serious strain where no regeneration is occurring.20

But these are faint hopes. In general, one would hope that the methods and conditions tested so far are at least in shouting distance of being the right formula close enough to be at least a little more encouraging.

Initially promising in principle, I predict that PRP will now be mired in trumped-up controversy for years. It will die a slow death, only beaten into submission over many years by a growing pile of underwhelming evidence, while its proponents continue to overconfidently sell the service and defend it from detractors, mainly by betting with dwindling odds that just the right formula can still be proven effective for just the right kind of patient. If so, great: I will be pleased to admit that my prediction was wrong! But Im betting against them for now.

After the centrifuge treatment, platelets are separated from the other components of blood.

My final word on this topic has to be placebo PRP is a perfect storm for it. Its got everything! Bearing in mind that its been thoroughly demonstrated that people get stronger placebo effects from treatment features trivial as a more potent pill colour

I can hardly imagine a better formula for a powerful expectation effect or relief from belief. Unfortunately, despite placebos weirdly good reputation, its powers are quite limited.21 The next time you hear a positive anecdote about PRP, remember: its probably the placebo talking.

The bar for worth a try is fairly high for normal folks. No invasive treatment can qualify for it without being proven at least safe. And you really need clear, consistent evidence of non-trivial benefit across several good trials before anything injected is worth a try. Before that its more like hey, its your knee, dont stab it!

The equation is always different for elite athletes, of course: the slightest edge could be a big deal. But that sword cuts both ways! It might help just a little, and that might matter a lot or it might hurt just a little, and that might matter a lot. Every athlete and coach is going to have a different opinion on whether that risk is worth it.

Five updates have been logged for this article since publication (2014). All PainScience.com updates are logged to show a long term commitment to quality, accuracy, and currency. more

I log any change to articles that might be of interest to a keen reader. Complete update logging started in 2016. Prior to that, I only logged major updates for the most popular and controversial articles.

See the Whats New? page for updates to all recent site updates.

January Added references to a pair of recent meta-analyses plus a sidebar about the problems with meta-analysis.

January Science update. Added a couple new references and did a little organizing and editing while I was at it. PRP for muscle strain is now clearly a big fat nothing burger. I suspect other indications will follow suit as the evidence quality continues to accumulate.

2019 General editing and minor updates. Spelled out the relationship to other cell and stem cell therapies much more clearly than before.

2018 Cited Mascarenhasetal on PRP for osteoarthritis (and its the usual story: garbage in, garbage out, no conclusion, no compelling evidence).

2018 Science update, added new meta-analysis of PRP for muscle strain, Grassietal.

2014 Publication.

Tendinitis versus tendonitis: Both spellings are acceptable these days, but the first is the more legitimate, while the second is just an old misspelling that has become acceptable only through popular use, which is a thing that happens in English. The word is based on the Latin tendo which has a genitive singular form of tendinis, and a combining form that is therefore tendin. (Source: Stedmans Electronic Medical Dictionary.)

Tendinitis vs tendinopathy: Both are acceptable labels for ticked off tendons. Tendinopathy (and tendinosis) are often used to avoid the implication of inflammation that is baked into the term tendinitis, because the condition involves no signs of gross, acute inflammation. However, recent research has shown that inflammation is actually there, its just not obvious. So tendinitis remains a fair label, and much more familiar to patients to boot.

The full text of this paper concludes:

Recent systematic reviews on the topic conclude that there is still a paucity of high-quality data providing sufficient evidence to support or disprove the clinical utility of PRP in symptomatic osteoarthritis of the knee. There is even less clinical evidence supporting its use in other joints or in the treatment of focal osteochondral defects despite the basic science evidence in favor of its use. In addition, not all basic science and clinical studies on PRP have concluded it has positive effects.

So garbage in, garbage out, no real conclusions possible: not enough good data even for the knee, even less for other joints. And theres contradictory evidence.

Read more from the original source:
Platelet-Rich Plasma: Does It Work? - http://www.PainScience.com

Can fasting reverse your ‘biological’ age? It can, according to Goop Lab experts – CNET

Gwyneth Paltrow gets a vampire facial in the fourth episode of Goop Lab.

Netflix's The Goop Lab follows Gwyneth Paltrow and the team that runs her wellness brand, Goop, as they experience various alternative wellness practices, from meeting with a psychic to taking aworkshop about how to orgasm. In The Goop Lab's fourth episode, The Health Span Plan, Paltrow, chief content officer Elise Loehnan and Goop's marketing VP Wendy Lauria explore the societal obsession with antiaging and the often expensive lengths many go to avoid it.

In their quest for eternal youth, members of the Goop staff try several different diets reported to reduce the risk of age-related disease, including fasting, veganism and pescatarianism. Paltrow and her team also set out on a quest to find "more natural" alternatives to plastic surgery and fillers, like facials and acupuncture.

Aging is one of many things that medicine can't stop, so that raises the question: Is there any validity to these diets and treatments? Can you really slow down the aging process with food? That's what The Goop Lab sets out to determine and the results are, surprisingly, somewhat valid.

The Health Span Plan episode explores diets and skincare treatments that claim to have antiaging benefits.

The Goop team chats with Valter Longo, the director of the University of Southern California's Longevity Institute, about the practice of fasting and how it can have positive effects on health. He promotes his fasting mimicking diet in the episode (for which he has a book and a $250 diet kit that Paltrow tries). Notably, the group doesn't talk about other forms of fasting -- such as intermittent fasting or alternate-day fasting -- which can have the same health benefits as Longo's diet.

Paltrow also talks with Morgan Levine, who studies aging at the Yale Department of Pathology. Levine developed a method of calculating a person's "biological age," based on several factors that intend to predict how likely you are to get age-related diseases or be at risk for early death.

Paltrow, Loehnan and Lauria are tested for their biological age before starting a new diet for three weeks. Lauria followed a vegan diet and Loehnan did a pescatarian diet, while Paltrow uses Longo's kit (which includes a nut bar, soup packets and kale crackers -- appetizing, huh?) for a five-day fast.

At the end of the three weeks, all three have their "biological ages" retested. The only person whose age did not "lower" was Lauria.

To round out this antiaging episode, all of the women try three different facial treatments -- acupuncture, facial threading and a vampire facial -- that are supposed to be more natural than using typical dermatological treatments such as skin fillers and Botox injections.

Loehnen tries facial acupuncture, which is reported to boost collagen production. Lauria gets a "facial threading" treatment that involves sewing a plastic thread that dissolves after nine months into her face in an effort to boost collagen and lift the face.

A Goop employee tries facial threading, a less invasive way to get the effect of a face lift.

Finally, Paltrow gets a "vampire facial," which is when a facialist extracts platelet rich plasma from your blood, and then microneedles it into the skin on your face. The PRP is supposed to help the skin resurface and look rejuvenated. Paltrow seems a bit weirded out by the process but notes that there's an "overuse of that stuff," (referring to injections, fillers and plastic surgery), and at least "this is your own blood and not a toxin, it's a more natural way."

Right now, there is a lot of hype surrounding fasting, intermittent fasting and ketosis and how those diets might benefit our overall health. It's not all hype -- there's definitely some sound science here and it's likely to keep expanding.

During the episode, Longo presents his fasting mimicking diet, which involves "tricking" the body into a fasting state while allowing specific amounts of food for at least five days. The idea is to give your body just enough nutrients that it thinks it's fasting, but not so few that you encounter the negative effects of prolonged fasting like a weakened immune system and nutritional deficiencies.

Fasting can help improve your overall health, some studies have shown.

Longo says that his clinical trials on the fasting mimicking diet showed to "reduce risk factors for multiple age-related diseases." That's not totally bunk -- science shows that when you restrict calories for certain periods of time, it does promote longevity. A study on this type of fasting did show that it can be effective in improving health markers that put you at risk for age-related diseases such as BMI, body fat percentage and blood pressure. Fasting can also lower inflammation levels in the body, improve cognitive impairment in miceand can decrease insulin-like growth factor, a hormone linked to cancer. The research is promising.

While Longo's diet might be scientifically sound, I found it hard to wrap my mind around the idea that eating processed, packaged foods for five days could actually be better for you than eating whole, unprocessed foods. Surely you can hit the same macronutrient targets (low carb, low protein and a total of 750-1,000 calories per day) he cites is necessary to "trick your body that it's fasting" with real food?

I'd be interested in seeing studies on groups who do the fasting mimicking diet versus groups that follow a pescatarian diet (as Loehnan did in the show). Also, I'd like to see results in a study of participants who follow the fasting mimicking diet with Longo's food packets and bars versus the same exact macronutrients in whole food form. My guess is that the results could be pretty different.

The facial treatments in the episode are pretty extreme. While they are touted as "more natural" alternatives to plastic surgery or fillers, Goop did not provide much information on why these treatments are "better" for you.

When each practitioner did each treatment, it sounded more like an infomercial about why you should do it, rather than a scientifically backed procedure. The episode lacked real information or science on if these treatments are actually safe, and how they compare to fillers or Botox. No one (at least that we could see) challenged the practitioners about the safety or quality of what was going on.

Facial acupuncture is said to help stimulate the production of collagen in the skin.

The science behind facial acupuncture is promising, but there's still a lot of work to be done. As for the facial threading, aka the noninvasive face lift, a study published in JAMAconcluded that the results of the threading face lift are not effective enough to justify the patient's risk of potential complications from the procedure.

I would describe the facial threading procedure more as a cosmetic procedure and less of a facial treatment. Even though the Goop staff say it's more "natural" than a face lift, it seems pretty invasive to me. You see the doctor literally sew a plastic thread into her face and if that isn't invasive plastic surgery, I don't know what is. Nothing about this treatment says "natural alternative" to me. It just says, "here is another way to get a face lift, and it's temporary."

Goop has long been criticized for presenting highly inaccessible treatments, and that's the same in this episode. The vampire facial costs over $1,000, and the facial threading pricing can start at $1,500 and go up to over $4,000. Facial acupuncture is typically less expensive, but it depends on where you go and how many treatments you get.

There's nothing wrong with showing what these extreme treatments are like, it makes for entertaining television. But if Goop wanted to better serve its audience, perhaps it would have been more helpful to show more accessible options for natural beauty products, regimens or other useful skincare advice.

This episode of The Goop Lab presents a few valid and several questionable antiaging practices for your body and face. While fasting to improve your overall health is backed up by science, there are plenty of other more accessible and doable ways to improve your health through nutrition, exercise and lifestyle alone.

Focusing on the basics like sleep, drinking water, moving more and lowering stress seems more realistic, and then you can experiment with fasting if you think it could help you. Fasting is not a very accessible wellness trend in that it's difficult to do, you should do it under the supervision of a specialist, certain health conditions can prevent you from doing it and it can be really triggering for someone who has a history of eating disorders.

Because of this, fasting is not my favorite wellness topic to explore, and I would have loved to see Goop cover more of the actual science on the benefits other diets such as pescatarianism and veganism, or even better the benefits of eating more plant-based diet versus a restrictive plan like veganism or vegetarianism.

As for the facial treatments, I found it interesting to see the different procedures on the market, but unrelatable for someone who can't afford to drop $1,000 and up on a treatment. It would have been much more interesting to me if Goop had talked to skincare experts, dermatologists and other pros in the space who can teach people about good skincare regimens, habits, ingredients and explain what clean or natural beauty products can help.

Now playing: Watch this: Impossible Foods CEO talks pork and the future of plant-based...

7:38

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.

Continue reading here:
Can fasting reverse your 'biological' age? It can, according to Goop Lab experts - CNET

Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal C | CCID – Dove Medical Press

John T Lear,1 Axel Hauschild,2 Eggert Stockfleth,3 Nicholas Squittieri,4 Nicole Basset-Seguin,5 Reinhard Dummer6

1Manchester Royal Infirmary, Manchester, UK; 2Klinik Fr Dermatologie, Venerologie Und Allergologie Universittsklinikum Schleswig-Holstein, Kiel, Germany; 3Universittshautklinik Bochum, Bochum, Germany; 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA; 5Department of Dermatology, Hpital Saint Louis, Paris, France; 6Skin Cancer Center University Hospital, Zrich, Switzerland

Correspondence: John T LearUniversity of Manchester, 46 Grafton Street, Manchester M13 9NT, UKTel +44 161 276 4173Fax +44 161 276 8881Email john.lear@srft.nhs.uk

Nevoid basal cell carcinoma syndrome (NBCCS), or Gorlin syndrome, is a rare hereditary disease characterized by the development of multiple cutaneous basal cell carcinomas (BCCs) from a young age.1 Loss-of-function germline mutations in the hedgehog-related patched 1 (PTCH1) tumor suppressor gene are the most common cause of NBCCS.1 The hedgehog signaling pathway plays a major role in embryonic development, and in adulthood, is involved in the renewal and maintenance of distinct tissues, including hair follicles, muscle stem cells, and gastric epithelium.2 Its abnormal activation is thought to drive the formation of both sporadic BCCs and those resulting from NBCCS.1 Patients with NBCCS inherit one inactive copy of PTCH1 and then acquire a second-hit mutation, resulting in hedgehog pathway activation and BCC formation.1 Mutations in Suppressor of fused (SUFU) or the PTCH1 homolog PTCH2 have also been found in a subset of patients meeting criteria for NBCCS.1,3

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See original here:
Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal C | CCID - Dove Medical Press

People who develop Parkinson’s before 50 may have been born with damaged brain cells, says study – MEAWW

People who develop Parkinson's disease at a young age might have malfunctioning brain cells -- even before birth. A drug used to treat pre-cancers of the skin may help treat the condition, finds a new study. At least 500,000 people in the US are diagnosed with Parkinson's every year, a majority of them over the age of 60. But about 10% of them develop the condition young -- between 21 and 50 years. People develop the disease when the brain nerve cells that make dopamine -- a substance that helps coordinate muscle movement -- malfunction or die. Consequently, these patients experience difficulty moving due to stiff muscles and tremors. Most often, young-onset patients have a family history of Parkinsons disease.

"Young-onset Parkinson's is especially heartbreaking because it strikes people at the prime of life," said Dr. Michele Tagliati, director of the Movement Disorders Program, vice-chair, and professor in the Department of Neurology at Cedars-Sinai. "This exciting new research provides hope that one day we may be able to detect and take early action to prevent this disease in at-risk individuals," says Dr Tagliati, co-author of the study.

In this study, the team turned cells from these Parkinson's patients into a kind of stem cell, meaning they turned adult cells into an embryo-like state. These cells can be programmed into developing into any cell types, including muscles, nerves or heart, for instance. The team turned these stem cells into cells that produce dopamine and grew them in their lab.

"Our technique gave us a window back in time to see how well the dopamine neurons might have functioned from the very start of a patient's life," said senior author Dr. Clive Svendsen, director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute and professor of Biomedical Sciences and Medicine at Cedars-Sinai.

When the team observed these cells, they saw an abnormal accumulation of a toxic protein called alpha-synuclein, which is seen in patients with most forms of Parkinson's disease. This accumulation could be the result of malfunctioning "trash cans".

These trash cans of the dopamine-producing cells called lysosomes are tasked with the breaking down and the disposing of proteins - but they failed to do so in young-onset Parkinson's patients. As a result, the toxic protein buildup ends up damaging dopamine-producing cells.

"The cells of the brain cannot dispose of the toxic protein called synuclein a hallmark of dying neurons in Parkinsons disease even before birth. This does not kill the neurons until much later in life though," the researchers tell MEA WorldWide (MEAWW). "Now we know that this starts so early in life we can think about ways to reduce this protein early and use this model as a way to detect whether the Parkinsons is starting," they add.

Further, the team also tested several drugs that might reverse the abnormality seen in these cells. They found that that one drug, dubbed PEP005, which is already approved by the Food and Drug Administration for treating precancers of the skin, proved effective in lab studies and mice. The drug brought down the levels of the toxic protein.

Encouraged by these positive results in the young-onset patients, the team is now testing whether these findings hold in patients who develop Parkinson's after the age of 50. "While we have shown our drug is effective in this cell model, it needs to be validated in actual patients before it is proven to be a treatment for Parkinsons. These studies are being planned," they add.

The study has been published in Nature Medicine.

Read the original here:
People who develop Parkinson's before 50 may have been born with damaged brain cells, says study - MEAWW

2020 Induced Pluripotent Stem Cells (iPSCs) Study: Global Markets, Technologies, Applications and Companies – Yahoo Finance

Dublin, Jan. 30, 2020 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cells: Global Markets" report has been added to ResearchAndMarkets.com's offering.

This study is focused on the market side of iPSCs rather than its technical side.

It has been over 10 years since the discovery of induced pluripotent stem cell (iPSC) technology. The market has gradually become an important part of the life sciences industry during recent years. Particularly for the past five years, the global market for iPSCs has experienced rapid growth.

The report includes:

The report has identified several key drivers for the rapidly growing market:

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Overview

Chapter 4 Induced Pluripotent Stem Cell Applications

Chapter 5 Induced Pluripotent Stem Cell Market Segmentation and Forecast

Chapter 6 Induced Pluripotent Stem Cell Research Application Market

Chapter 7 Drug Discovery and Development Market

Chapter 8 Induced Pluripotent Stem Cell Contract Service Market

Chapter 9 Induced Pluripotent Stem Cell Clinical Application Market

Chapter 10 Research Market Trend Analysis

Chapter 11 Clinical Application Market Trend Analysis

Chapter 12 Company Profiles

Chapter 13 Conclusions

For more information about this report visit https://www.researchandmarkets.com/r/tvap34

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read more:
2020 Induced Pluripotent Stem Cells (iPSCs) Study: Global Markets, Technologies, Applications and Companies - Yahoo Finance

Can Parkinsons be prevented as it stealthily develops? – Big Think

Parkinson's disease comes with slowness, rigidity, tremors, and loss of balance due to an insufficiency of the dopamine that coordinates muscle movement. This disease, of which the rate of diagnosis is rising, occurs when the neurons responsible for producing dopamine malfunction or die. About 500,000 Americans are diagnosed with Parkinson's each year.

Most of the time, Parkinson's disease is a condition of the elderly, diagnosed in people 60 and older. However, about 10% of the time, it's detected in people between 21 and 50. "Young-onset Parkinson's is especially heartbreaking because it strikes people at the prime of life," says Michele Tagliati, an author of a new study from Cedars-Sinai.

The study of brain cells from Parkinson's younger victims has found that the misbehaving neurons are present long before diagnosis typically taking some 20 or 30 years to produce detectable symptoms and may even be present prior to birth. The revelation raises hope for combatting Parkinson's because there's already an approved drug that can mitigate the damage done by the troublemaking neurons before the disease ever appears.

The research is published in the journal Nature Medicine.

Image source: Kateryna Kon/Shutterstock

The authors' investigation began with an examination of neurons based on cells from young-onset Parkinson's (YOPD) patients who had no known mutations. From the cells, induced pluripotent stem cells (iPSCs) were generated and differentiated into dishes containing cultures of dopamine neurons. Senior study author Clive Svendsen says, "Our technique gave us a window back in time to see how well the dopamine neurons might have functioned from the very start of a patient's life."

The scientists observed lysosomes within the YOPD neurons malfunctioning. Since lysosomes are counted on as "trash cans" for unnecessary or depleted proteins, the castoff chemicals began to pile up. In particular, substantial accumulations of soluble -synuclein, a protein implicated in different types of Parkinson's, were seen.

Says Svendsen, "What we are seeing using this new model are the very first signs of young-onset Parkinson's,"revealing that, "It appears that dopamine neurons in these individuals may continue to mishandle -synuclein over a period of 20 or 30 years, causing Parkinson's symptoms to emerge."

The researchers also saw unexpectedly high levels of the enzyme protein kinase C in its active form, though what that has to do with Parkinson's, if anything, is unknown.

Image source: sruilk/Shutterstock

The researchers tested a number of drugs on the cultures to see if any might address the observed accumulations of -synuclein. (They performed parallel tests of laboratory mice.) One drug, PEP005, which is already approved by the FDA for treating skin pre-cancers, did effectively reduce the -synuclein buildup, both in the iPSCs and the mice.

Since PEP005 is currently administered in gel form for treating skin, the researchers are now exploring how the drug might be modified so it can be delivered directly to the brain. The team also plans follow-on research to see if their findings apply equally to forms of Parkinson's beyond YOPD.

Related Articles Around the Web

Read more:
Can Parkinsons be prevented as it stealthily develops? - Big Think

Unpicking the proteome in single cells – Science Magazine

Recently, the throughput of single-cell RNA-sequencing (transcriptomics) and genomics technologies has increased more than a 1000-fold. This increase has powered new analyses: Whereas traditional analysis of bulk tissue averages all differences between the diverse cells comprising such samples, single-cell analysis characterizes each individual cell and thus has enabled the discovery and classification of previously unknown cell states. Yet, the nucleic-acidbased technologies are effectively blind to an important group of biological regulators: proteins. Fortunately, emerging mass-spectrometry (MS) technologies that identify and quantify proteins promise to deliver similar gains to single-cell protein analysis. These proteomic technologies will enable high-throughput investigation of key biological questions, such as signaling mechanisms based on protein binding, modifications, and degradation, that have long remained elusive.

The abundance and activity of many proteins are regulated by degradation and posttranslational modifications (PTMs) that cannot be inferred from genomic and transcriptomic measurements. Moreover, genomic and transcriptomic sequencing cannot report directly on protein-protein interactions and protein localization, which are critical for numerous signaling pathways (13). The extracellular matrix surrounding each cell is composed of proteins whose chemical and physical properties, such as stiffness, can also play vital roles in regulating cellular behavior, including proliferation, migration, metastasis, and aging (4). Yet, current single-cell sequencing tools provide little information about the protein composition and biological roles of the extracellular matrix (35). Thus, methodologies are needed that can directly analyze a broad repertoire of intracellular, membrane-bound, and extracellular proteins at the single-cell level.

Single-cell protein analysis has a long history, but the conventional technologies have relatively limited capabilities (6, 7). Most proteomics methods, such as mass cytometry, cellular indexing of transcriptomes and epitopes by sequencing, RNA expression and protein sequencing, and CO-Detection by indEXing, rely on antibodies to detect select protein epitopes and can analyze only a few dozen proteins per cell (6) (see the figure). However, many antibodies have low specificity for their targets, which results in nonspecific protein detection. Indeed, fewer than a third of more than a thousand antibodies tested in multiple laboratories bind specifically to their cognate targets (6). As a result, $800 million is wasted worldwide annually on purchasing nonspecific antibodies and even more on experiments following up flawed hypotheses based on these nonspecific antibodies (8). Although some highly specific and well-validated antibodies can be useful to analyze a few proteins across many cells, the low specificity and limited throughput of the current generation of single-cell protein analytical methods pose challenges for understanding the interactions and functions of proteins at single-cell resolution.

These challenges are being addressed by emerging technologies for analyzing single cells by MS without the use of antibodies, such as Single Cell ProtEomics by MS (SCoPE-MS) and its second generation, SCoPE2. These methods allow the quantification of thousands of proteins across hundreds of single-cell samples (9, 10) (see the figure). A key driver of this progress was the development of multiplexed experimental designs in which proteins from single cells and from the total cell lysate of a small group of cells (called carrier proteins) are barcoded and then combined (9, 10). With this design, the carrier proteins reduce the loss of proteins from single cells adhering to equipment surfaces while simultaneously enhancing peptide identification.

Other key drivers of progress include methods for clean and automated sample preparation, for which there is preliminary evidence (11), as well as rigorous computational approaches that incorporate additional peptide features, such as retention time, to determine peptide sequences from limited sample quantities (12). Further technological developments can increase the accuracy of quantification and numbers of analyzed cells by 100- to 1000-fold while affording quantification of protein modifications at single-cell resolution (7). For example, the carrier protein approach (9) can be extended to quantify PTMs by using a carrier composed of peptides with PTMs while avoiding the need to enrich modified proteins from single cells and, thus, enrichment-associated protein losses.

Although current methods can quantify proteins present at 50,000 copies per cell (which is the median protein abundance in a typical human cell), increased efficiency of peptide delivery to MS analyzers, e.g., by increasing the time over which peptide ions (proteins are fragmented into peptides and ionized in MS analysis) are sampled (7, 13), will increase sensitivity to proteins present at only 1000 copies per cell. In general, the emerging technologies offer a trade-off between quantifying low-abundance proteins with increased accuracy or quantifying more proteins. This trade-off can be mitigated by simultaneously sampling multiple peptides (7). Over the next few years, improvements in sample preparation, peptide separation and ionization, and instrumentation are likely to afford quantification of more than 5000 proteins across thousands of single cells, while targeted approaches are poised to enable analysis of even low-abundance proteins of interest (7).

MS methods have the potential to measure not merely the abundance and PTMs of proteins in single cells, but also their complexes and subcellular localization. When proteins form a complex, polypeptide chains from different proteins can get close enough to be cross-linked by small molecules. Because only proteins in the complex are likely to be cross-linked, the abundance of such peptides can report directly on complex formation and composition. Some cross-linked peptide pairs are observed only with specific complex conformations, and thus these pairs can be useful in distinguishing active and inactive complexes. Furthermore, if a protein complex is close to organelles, targeted MS analysis of cross-linked peptides between the complex and organelle-specific proteins may report on the subcellular localization. Such analysis has not yet been applied to single-cell MS, but is likely to be feasible.

Realizing these exciting prospects requires concerted effort and community standards devoted to ensuring that hype does not overshadow scientific rigor. For example, systematic artifacts, such as contaminant proteins introduced to single-cell samples during their preparation or chromatographic separation, may result in reproducible measurements. Despite their reproducibility, such measurements do not reflect protein abundances in single cells. If reproducibility is misinterpreted as accuracy, the resulting errors may erode the credibility of this emerging field.

Single-cell proteomics will find many applications in biomedical research. Some applications, such as classifying cell states and cell types, overlap with those of single-cell RNA sequencing. Other applications can only be achieved by measuring proteins. For example, the development of cells for regenerative therapies through the rational engineering of directed differentiation may benefit from single-cell proteomics. Although there has been much progress in developing directed differentiation protocols for certain cell types, these efforts tend to rely on trial-and-error approaches (14). Many of the resulting protocols remain relatively inefficient: Only a fraction of the cells differentiate into the desired cell type, and such cells may not fully recapitulate the desired physiological phenotypes (14).

Traditional methods identify and quantify a limited number of proteins based on antibodies barcoded with DNA sequences, fluorophores, or transition metals. Emerging single-cell mass-spectrometry (MS) methods will allow high-throughput analysis of proteins and their posttranslational modifications, interactions, and degradation.

Next-generation single-cell proteomics analysis offers an alternative to this trial-and-error approach. If the signaling events (usually mediated by protein interactions and PTMs) that guide cell differentiation during normal development can be identified, it should be possible to recapitulate such signaling in induced pluripotent stem cells. This would require identifying the signaling processes that lead to the desired cell types and then simulating them by using agonists and/or antagonists. Whereas single-cell RNA sequencing can identify the cells of interest, the amounts of messenger RNA are poor surrogates for the signaling activities mediated by protein modifications, such as phosphorylation or protein cleavage (2, 15). Single-cell proteomics could provide a robust means to characterize such signaling dynamics.

Another potential application is the identification of the sets of molecular interactions leading from a genotype or a stimulus to a phenotype of interest. This goal presents a substantial challenge in part because interacting molecules within a pathway are rarely measured across a large range of phenotypic states to constrain cellular network models. This limitation is particularly evident for proteins and their PTMs (13). Yet, proteins are key regulators in cells; models that ignore them cannot capture molecular mechanisms involving protein interactions. For example, the absence of direct protein measurements compromises the ability to study signaling networks because most of the key regulatory variables are missing from the data. Currently, when proteins and their PTMs are measured in bulk tissues, they have been analyzed in a few tens to a few hundreds of samples (2, 3). Analyzing so few samples tends to require assumptions about the specific sets of interactions and functional dependencies that occur between interacting proteins and molecules. Such assumptions fundamentally underpin the inferred biological mechanisms and undermine their validity (3).

Next-generation single-cell protein analytical technologies will reduce these assumptions and thus increase the validity of inferred mechanisms. If proteins, RNAs, DNA, and metabolites are measured across tens of thousands of individual cells, it may be possible to identify direct molecular interactions without the need to make assumptions about basic aspects of the pathway. Next-generation single-cell analysis is poised to generate just this type of data, which should underpin systems-level understanding of intracellular and extracellular regulatory mechanisms.

Single-cell proteomics may also have clinical applications. Protein measurements from limited clinical samples are attractive because they afford direct measurements of deregulated signaling pathways that drive disease. Furthermore, measuring protein concentrations allows the development of assays to test therapies that induce protein degradation, which are among the most rapidly growing therapeutic modalities (15). Additionally, protein assays may be more robust than RNA-sequencing assays because protein concentrations are less noisy and proteins degrade more slowly than RNAs. Moreover, the cost of protein analysis will decrease proportionately with increased multiplexing (7, 11).

The latest generation of nucleic acidbased single-cell analytical methods has opened the door to describing the varied and complex constellation of cell states that exist within tissue. The next generation of proteomics-based methods will complement current methods while shifting the emphasis from description toward functional characterization of these cell states.

Acknowledgments: N.S. is an inventor on patent application 16/251,039. N.S. is supported by a New Innovator Award from the National Institute of General Medical Sciences (award no. DP2GM123497).

View post:
Unpicking the proteome in single cells - Science Magazine

Osaka University transplants iPS cell-based heart cells in world’s first clinical trial – The Japan Times

OSAKA An Osaka University team said it has carried out the worlds first transplant of cardiac muscle cells created from iPS cells in a physician-initiated clinical trial.

In the clinical project to verify the safety and efficacy of the therapy using induced pluripotent stem cells, Yoshiki Sawa, a professor in the universitys cardiovascular surgery unit, and colleagues aim to transplant heart muscle cell sheets over the course of three years into 10 patients suffering from serious heart malfunction caused by ischemic cardiomyopathy.

As part of its first step in the project, the team conducted an operation on a patient this month, which was a success. The patient has since moved to the general ward at a hospital.

The cells on the degradable sheets attached to the surface of the patients hearts are expected to grow and secrete a protein that can regenerate blood vessels and improve cardiac function. The iPS cells have already been derived from healthy donors blood cells and stored.

Each sheet is around 4 to 5 centimeters wide and 0.1 millimeter thick.

The team will continue to monitor the patient over the next year.

I hope that (the transplant) will become a medical technology that will save as many people as possible, as Ive seen many lives that I couldnt save, Sawa said at a news conference.

The researchers said Monday they decided to conduct a clinical trial instead of a clinical study in hopes of obtaining approval from the health ministry for clinical applications as soon as possible.

The trial involves stringently evaluating risks, particularly cancer probabilities, and the efficacy of transplanting some 100 million cells per patient that may include tumor cells.

This is the second iPS cell-based clinical trial in Japan. The first was conducted on eye disease patients by the Riken research institute.

More here:
Osaka University transplants iPS cell-based heart cells in world's first clinical trial - The Japan Times